Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines

In vivo dendritic-cell targeting constitutes a promising strategy for anticancer vaccination. Here, we discuss the usage of multivalent DC-SIGN-targeting glycan platforms that allow for the efficient routing of antigens to the endo-lysosomal pathway as well as to a yet uncharacterized cross-presenta...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Vallejo, Juan J., Unger, Wendy W. J., Kalay, Hakan, van Kooyk, Yvette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601176/
https://www.ncbi.nlm.nih.gov/pubmed/23525136
http://dx.doi.org/10.4161/onci.23040
_version_ 1782475730698895360
author García-Vallejo, Juan J.
Unger, Wendy W. J.
Kalay, Hakan
van Kooyk, Yvette
author_facet García-Vallejo, Juan J.
Unger, Wendy W. J.
Kalay, Hakan
van Kooyk, Yvette
author_sort García-Vallejo, Juan J.
collection PubMed
description In vivo dendritic-cell targeting constitutes a promising strategy for anticancer vaccination. Here, we discuss the usage of multivalent DC-SIGN-targeting glycan platforms that allow for the efficient routing of antigens to the endo-lysosomal pathway as well as to a yet uncharacterized cross-presentation mechanism inducing CD4(+) and CD8(+) T-cell responses.
format Online
Article
Text
id pubmed-3601176
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36011762013-03-22 Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines García-Vallejo, Juan J. Unger, Wendy W. J. Kalay, Hakan van Kooyk, Yvette Oncoimmunology Author's View In vivo dendritic-cell targeting constitutes a promising strategy for anticancer vaccination. Here, we discuss the usage of multivalent DC-SIGN-targeting glycan platforms that allow for the efficient routing of antigens to the endo-lysosomal pathway as well as to a yet uncharacterized cross-presentation mechanism inducing CD4(+) and CD8(+) T-cell responses. Landes Bioscience 2013-02-01 /pmc/articles/PMC3601176/ /pubmed/23525136 http://dx.doi.org/10.4161/onci.23040 Text en Copyright © Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
García-Vallejo, Juan J.
Unger, Wendy W. J.
Kalay, Hakan
van Kooyk, Yvette
Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
title Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
title_full Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
title_fullStr Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
title_full_unstemmed Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
title_short Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
title_sort glycan-based dc-sign targeting to enhance antigen cross-presentation in anticancer vaccines
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601176/
https://www.ncbi.nlm.nih.gov/pubmed/23525136
http://dx.doi.org/10.4161/onci.23040
work_keys_str_mv AT garciavallejojuanj glycanbaseddcsigntargetingtoenhanceantigencrosspresentationinanticancervaccines
AT ungerwendywj glycanbaseddcsigntargetingtoenhanceantigencrosspresentationinanticancervaccines
AT kalayhakan glycanbaseddcsigntargetingtoenhanceantigencrosspresentationinanticancervaccines
AT vankooykyvette glycanbaseddcsigntargetingtoenhanceantigencrosspresentationinanticancervaccines

Ejemplares similares